Puma Biotechnology Inc (PBYI.N)

PBYI.N on New York Stock Exchange

23 Sep 2016
Change (% chg)

$2.10 (+3.18%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for PBYI.N


Puma Biotechnology, Inc. is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the global development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), which the Company is... (more)


Beta: 0.16
Market Cap(Mil.): $2,212.13
Shares Outstanding(Mil.): 32.49
Dividend: --
Yield (%): --


BRIEF-Puma Biotechnology's marketing authorization application for neratinib validated by EMA

* Marketing authorization application for neratinib has been validated by European Medicines Agency Source text (http://bit.ly/2bxvgWa) Further company coverage:

23 Aug 2016

U.S. RESEARCH ROUNDUP-D.R. Horton, Humana, Chicago Bridge & Iron

July 22 Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Adeptus Health, Chipotle Mexican Grill and Yadkin Financial, on Friday. HIGHLIGHTS * Chicago Bridge & Iron Co : Baird cuts to neutral * D.R. Horton Inc : BofA Merrill cuts to neutral from buy * Humana Inc : Wolfe Research raises to outperform * Community Bank System Inc : Sandler O'Neill cuts to

23 Jul 2016

BRIEF-Puma Biotech applies for marketing approval for breast cancer drug

* Submits NDA for PB272 (neratinib) to U.S. FDA for extended adjuvant treatment of HER2-positive early stage breast cancer Source text for Eikon: Further company coverage:

22 Jul 2016

BRIEF-Puma Biotechnology announces 5-year data on breast cancer

* "look forward to obtaining full 5-year dfs data, which we anticipate will be available in 2017"

22 Jul 2016

BRIEF-Puma Biotechnology Inc submits MAA for neratinib

* Puma biotechnology submits marketing authorization application (MAA) for PB272 (neratinib) as extended adjuvant treatment of her2-positive early stage breast cancer in europe

27 Jun 2016

BRIEF-Paulson & Co ups share stake in Puma Biotechnology Inc by 52.8 pct to 70,300 shares - Sec Filing

* Paulson & Co ups share stake in Puma Biotechnology Inc by 52.8 pct to 70,300 shares - Sec Filing

17 May 2016

BRIEF-Puma Biotechnology reports Q1 loss per share $2.19

* Puma biotechnology reports first quarter 2016 financial results

11 May 2016

Earnings vs. Estimates